Altimmune Inc (ALT)
8.40
+0.35
(+4.35%)
USD |
NASDAQ |
Nov 21, 16:00
8.51
+0.11
(+1.31%)
After-Hours: 20:00
Altimmune Enterprise Value: 433.17M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 433.17M |
| November 19, 2024 | 391.92M |
| November 18, 2024 | 369.16M |
| November 15, 2024 | 401.88M |
| November 14, 2024 | 461.98M |
| November 13, 2024 | 537.73M |
| November 12, 2024 | 535.59M |
| November 11, 2024 | 383.39M |
| November 08, 2024 | 406.86M |
| November 07, 2024 | 391.21M |
| November 06, 2024 | 380.54M |
| November 05, 2024 | 360.62M |
| November 04, 2024 | 343.55M |
| November 01, 2024 | 340.00M |
| October 31, 2024 | 340.00M |
| October 30, 2024 | 341.42M |
| October 29, 2024 | 384.10M |
| October 28, 2024 | 359.20M |
| October 25, 2024 | 336.44M |
| October 24, 2024 | 341.78M |
| October 23, 2024 | 338.58M |
| October 22, 2024 | 344.27M |
| October 21, 2024 | 351.38M |
| October 18, 2024 | 349.96M |
| October 17, 2024 | 343.55M |
| Date | Value |
|---|---|
| October 16, 2024 | 348.53M |
| October 15, 2024 | 361.34M |
| October 14, 2024 | 317.95M |
| October 11, 2024 | 308.70M |
| October 10, 2024 | 288.79M |
| October 09, 2024 | 295.19M |
| October 08, 2024 | 304.44M |
| October 07, 2024 | 294.48M |
| October 04, 2024 | 303.72M |
| October 03, 2024 | 298.04M |
| October 02, 2024 | 306.57M |
| October 01, 2024 | 307.99M |
| September 30, 2024 | 297.32M |
| September 27, 2024 | 294.92M |
| September 26, 2024 | 319.09M |
| September 25, 2024 | 332.59M |
| September 24, 2024 | 341.12M |
| September 23, 2024 | 346.80M |
| September 20, 2024 | 388.74M |
| September 19, 2024 | 373.10M |
| September 18, 2024 | 363.15M |
| September 17, 2024 | 373.10M |
| September 16, 2024 | 373.81M |
| September 13, 2024 | 395.13M |
| September 12, 2024 | 339.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-33.51M
Minimum
Aug 25 2023
984.81M
Maximum
Jul 20 2020
249.56M
Average
255.66M
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 742.91B |
| Viking Therapeutics Inc | 4.812B |
| Amgen Inc | 206.13B |
| Avid Bioservices Inc | 900.06M |
| NovaBay Pharmaceuticals Inc | 2.745M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.84M |
| Revenue (Quarterly) | 0.005M |
| Total Expenses (Quarterly) | 24.77M |
| EPS Diluted (Quarterly) | -0.32 |
| Profit Margin (Quarterly) | -456.9K% |
| Earnings Yield | -18.69% |
| Normalized Earnings Yield | -18.69 |